Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC By Ogkologos - July 23, 2026 62 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER Cohort 3 study Source RELATED ARTICLESMORE FROM AUTHOR Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR Targeting CLDN18.2 with Zolbetuximab Prolongs Survival When Combined with mFOLFOX6 in... April 19, 2023 Modest Effectiveness of Screening Colonoscopy for the Prevention of Colorectal Cancer... October 10, 2022 Bean there done that: Can swapping to pulses be the new... February 11, 2022 Qué debe saber sobre las pruebas de ADN en el hogar... February 8, 2023 Load more HOT NEWS Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated... BRCA Gene Testing: Risks, Benefits, Costs, and Coverage FDA Authorizes Blood Test for Assessing Risk of Hereditary Cancers New Research in Treating Non-Small Cell Lung Cancer: 2022 North America...
